Wall Street analysts expect Blueprint Medicines Corp (NASDAQ:BPMC) to announce ($1.68) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Blueprint Medicines’ earnings, with the lowest EPS estimate coming in at ($1.88) and the highest estimate coming in at ($1.30). Blueprint Medicines reported earnings per share of ($1.23) during the same quarter last year, which indicates a negative year-over-year growth rate of 36.6%. The company is scheduled to report its next earnings report on Wednesday, February 20th.
According to Zacks, analysts expect that Blueprint Medicines will report full year earnings of ($5.25) per share for the current year, with EPS estimates ranging from ($5.45) to ($4.86). For the next financial year, analysts expect that the firm will report earnings of ($7.60) per share, with EPS estimates ranging from ($9.35) to ($5.98). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Blueprint Medicines.
Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Tuesday, October 30th. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.09). Blueprint Medicines had a negative return on equity of 36.72% and a negative net margin of 455.15%. The company had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $1.87 million. During the same period in the prior year, the firm earned ($0.96) EPS. The firm’s revenue for the quarter was down 86.4% on a year-over-year basis.
Several analysts recently issued reports on BPMC shares. Guggenheim started coverage on shares of Blueprint Medicines in a research note on Tuesday, September 18th. They set a “buy” rating and a $102.00 price objective for the company. Cowen reaffirmed a “buy” rating on shares of Blueprint Medicines in a research note on Sunday, October 7th. ValuEngine cut shares of Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 17th. BidaskClub cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Saturday, August 25th. Finally, Wedbush reissued an “outperform” rating and issued a $101.00 price target on shares of Blueprint Medicines in a research note on Monday, October 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. Blueprint Medicines presently has a consensus rating of “Buy” and an average price target of $97.14.
Shares of NASDAQ BPMC opened at $60.22 on Friday. Blueprint Medicines has a 12-month low of $57.44 and a 12-month high of $109.00. The stock has a market cap of $2.71 billion, a P/E ratio of -15.36 and a beta of 1.46. The company has a debt-to-equity ratio of 0.03, a current ratio of 10.05 and a quick ratio of 10.05.
In other news, insider Marion Dorsch sold 2,300 shares of the company’s stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $70.47, for a total value of $162,081.00. Following the transaction, the insider now directly owns 2,300 shares in the company, valued at approximately $162,081. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jeffrey W. Albers sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, November 5th. The stock was sold at an average price of $63.49, for a total transaction of $1,269,800.00. Following the completion of the transaction, the chief executive officer now owns 20,000 shares in the company, valued at $1,269,800. The disclosure for this sale can be found here. Corporate insiders own 3.15% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in BPMC. Dimensional Fund Advisors LP acquired a new stake in Blueprint Medicines during the 1st quarter worth approximately $3,940,000. Millennium Management LLC acquired a new stake in Blueprint Medicines during the 1st quarter worth approximately $5,906,000. Handelsbanken Fonder AB acquired a new stake in Blueprint Medicines during the 2nd quarter worth approximately $1,206,000. Xact Kapitalforvaltning AB lifted its holdings in Blueprint Medicines by 15.0% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 6,151 shares of the biotechnology company’s stock worth $390,000 after buying an additional 800 shares in the last quarter. Finally, Bank of Montreal Can acquired a new stake in Blueprint Medicines during the 2nd quarter worth approximately $154,000. Institutional investors own 99.73% of the company’s stock.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.